| Tbio | Integrin alpha-2 |
(Microbial infection) Integrin ITGA2:ITGB1 acts as a receptor for human rotavirus A (PubMed:12941907). Integrin ITGA2:ITGB1 acts as a receptor for human echoviruses 1 and 8 (PubMed:8411387).
This gene encodes the alpha subunit of a transmembrane receptor for collagens and related proteins. The encoded protein forms a heterodimer with a beta subunit and mediates the adhesion of platelets and other cell types to the extracellular matrix. Loss of the encoded protein is associated with bleeding disorder platelet-type 9. Antibodies against this protein are found in several immune disorders, including neonatal alloimmune thrombocytopenia. This gene is located adjacent to a related alpha subunit gene. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2012]
This gene encodes the alpha subunit of a transmembrane receptor for collagens and related proteins. The encoded protein forms a heterodimer with a beta subunit and mediates the adhesion of platelets and other cell types to the extracellular matrix. Loss of the encoded protein is associated with bleeding disorder platelet-type 9. Antibodies against this protein are found in several immune disorders, including neonatal alloimmune thrombocytopenia. This gene is located adjacent to a related alpha subunit gene. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2012]
Comments
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| BLEEDING DISORDER, PLATELET-TYPE, 9 | 1 | 0.0 | 0.0 |
| Endometriosis | 540 | 0.0 | 0.0 |
| Gliosis | 56 | 0.0 | 0.0 |
| Hyperalgesia | 83 | 0.0 | 0.0 |
| Retinal vein occlusion | 9 | 0.0 | 0.0 |
| Disease | Target Count |
|---|---|
| Thrombocytopenia | 197 |
| Decreased platelet count | 111 |
| Ecchymosis | 66 |
| FNAITP | 6 |
| Increased tendency to bruise | 66 |
| Prenatal onset | 139 |
| Disease | Target Count | P-value |
|---|---|---|
| lung carcinoma | 2843 | 2.0e-20 |
| malignant mesothelioma | 3232 | 8.9e-09 |
| non-small cell lung cancer | 2890 | 6.1e-08 |
| ependymoma | 4679 | 1.1e-06 |
| pancreatic cancer | 2398 | 3.4e-06 |
| glioblastoma | 5792 | 2.1e-05 |
| ulcerative colitis | 1819 | 4.3e-05 |
| atypical teratoid / rhabdoid tumor | 5112 | 6.0e-05 |
| cystic fibrosis | 1696 | 8.6e-05 |
| primary pancreatic ductal adenocarcinoma | 1109 | 2.3e-04 |
| ovarian cancer | 8520 | 3.2e-03 |
| primitive neuroectodermal tumor | 3035 | 4.3e-03 |
| intraductal papillary-mucinous neoplasm (IPMN) | 3291 | 8.8e-03 |
| adult high grade glioma | 3801 | 8.8e-03 |
| intraductal papillary-mucinous carcinoma (IPMC) | 2989 | 9.7e-03 |
| osteosarcoma | 7950 | 1.5e-02 |
| Breast cancer | 3578 | 2.9e-02 |
| progressive supranuclear palsy | 676 | 4.1e-02 |
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Vascular disease | 319 | 0.0 | 0.8 |
| Disease | log2 FC | p |
|---|---|---|
| adult high grade glioma | 1.500 | 8.8e-03 |
| atypical teratoid / rhabdoid tumor | 1.400 | 6.0e-05 |
| Breast cancer | 2.700 | 2.9e-02 |
| cystic fibrosis | 1.864 | 8.6e-05 |
| ependymoma | 2.200 | 1.1e-06 |
| glioblastoma | 1.900 | 2.1e-05 |
| intraductal papillary-mucinous carcinoma... | 2.700 | 9.7e-03 |
| intraductal papillary-mucinous neoplasm ... | 3.700 | 8.8e-03 |
| lung carcinoma | -2.400 | 2.0e-20 |
| malignant mesothelioma | -3.000 | 8.9e-09 |
| non-small cell lung cancer | 1.031 | 6.1e-08 |
| osteosarcoma | 1.939 | 1.5e-02 |
| ovarian cancer | -1.400 | 3.2e-03 |
| pancreatic cancer | 1.400 | 3.4e-06 |
| primary pancreatic ductal adenocarcinoma | 2.813 | 2.3e-04 |
| primitive neuroectodermal tumor | 2.200 | 4.3e-03 |
| progressive supranuclear palsy | -1.300 | 4.1e-02 |
| ulcerative colitis | 1.500 | 4.3e-05 |
MGPERTGAAPLPLLLVLALSQGILNCCLAYNVGLPEAKIFSGPSSEQFGYAVQQFINPKGNWLLVGSPWS 1 - 70 GFPENRMGDVYKCPVDLSTATCEKLNLQTSTSIPNVTEMKTNMSLGLILTRNMGTGGFLTCGPLWAQQCG 71 - 140 NQYYTTGVCSDISPDFQLSASFSPATQPCPSLIDVVVVCDESNSIYPWDAVKNFLEKFVQGLDIGPTKTQ 141 - 210 VGLIQYANNPRVVFNLNTYKTKEEMIVATSQTSQYGGDLTNTFGAIQYARKYAYSAASGGRRSATKVMVV 211 - 280 VTDGESHDGSMLKAVIDQCNHDNILRFGIAVLGYLNRNALDTKNLIKEIKAIASIPTERYFFNVSDEAAL 281 - 350 LEKAGTLGEQIFSIEGTVQGGDNFQMEMSQVGFSADYSSQNDILMLGAVGAFGWSGTIVQKTSHGHLIFP 351 - 420 KQAFDQILQDRNHSSYLGYSVAAISTGESTHFVAGAPRANYTGQIVLYSVNENGNITVIQAHRGDQIGSY 421 - 490 FGSVLCSVDVDKDTITDVLLVGAPMYMSDLKKEEGRVYLFTIKKGILGQHQFLEGPEGIENTRFGSAIAA 491 - 560 LSDINMDGFNDVIVGSPLENQNSGAVYIYNGHQGTIRTKYSQKILGSDGAFRSHLQYFGRSLDGYGDLNG 561 - 630 DSITDVSIGAFGQVVQLWSQSIADVAIEASFTPEKITLVNKNAQIILKLCFSAKFRPTKQNNQVAIVYNI 631 - 700 TLDADGFSSRVTSRGLFKENNERCLQKNMVVNQAQSCPEHIIYIQEPSDVVNSLDLRVDISLENPGTSPA 701 - 770 LEAYSETAKVFSIPFHKDCGEDGLCISDLVLDVRQIPAAQEQPFIVSNQNKRLTFSVTLKNKRESAYNTG 771 - 840 IVVDFSENLFFASFSLPVDGTEVTCQVAASQKSVACDVGYPALKREQQVTFTINFDFNLQNLQNQASLSF 841 - 910 QALSESQEENKADNLVNLKIPLLYDAEIHLTRSTNINFYEISSDGNVPSIVHSFEDVGPKFIFSLKVTTG 911 - 980 SVPVSMATVIIHIPQYTKEKNPLMYLTGVQTDKAGDISCNADINPLKIGQTSSSVSFKSENFRHTKELNC 981 - 1050 RTASCSNVTCWLKDVHMKGEYFVNVTTRIWNGTFASSTFQTVQLTAAAEINTYNPEIYVIEDNTVTIPLM 1051 - 1120 IMKPDEKAEVPTGVIIGSIIAGILLLLALVAILWKLGFFKRKYEKMTKNPDEIDETTELSS 1121 - 1181 //
